RxDoctor Payments Data

Robert Rosenberg, MD

MOHS-Micrographic Surgery · Fullerton, CANPI 1265433072

Payments from drug & device makers

$1,663in general payments, 2019–2025

Across 33 payments — averaging $50.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$374
  • AbbVie$364
  • Pfizer$262
  • Ortho Dermatologics, A Division Of Bausch Health US, LLC$209
  • Galderma Laboratories, L.p.$139
  • Johnson & Johnson$68
  • plus $247 from 7 others

What the payments were for

  • Food & beverage$1,663100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,663 in reported general payments places this provider in the 40th percentile of 144 mohs-micrographic surgery providers in California.

See all mohs-micrographic surgery providers in California

Medicare billing

Part B allowed, 2024
$186,622
Medicare patients
497
Services billed
2,250

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TremfyaGuselkumab20$262,000
Metronidazole59$3,570
Fluocinonide75$2,305
Tacrolimus14$2,103
Alclometasone Dipropionate48$1,880
Desonide15$1,299
Ketoconazole53$1,209
Clobetasol Propionate42$989
ValacyclovirValacyclovir Hcl11$816
Triamcinolone Acetonide92$529
Mometasone Furoate15$509
Gentamicin Sulfate13$447
Clindamycin Phosphate22$376
Hydrocortisone52$307
Prednisone24$188

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonTremfya$68$262,00020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 144 mohs-micrographic surgery providers in California.

Other mohs-micrographic surgery in Fullerton

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →